KMT2A and acute myeloid leukemia: In our analysis, we compared MLL-rearranged patient samples to CN-AML as a control, however even within this comparison there are likely additional splicing differences attributable in part to phenomena such as lineage skewing58, co-occurrence of spliceosome mutations within the patient cohort analyzed above44, or other yet-unidentified MLL fusion-specific transcriptional/splicing programs, hence isolation of a core splicing factor-associated program in vitro will only remain an approximation of molecular programs found in patients.